Published July 2026

Below is a list of medications recently reviewed by the MVP Pharmacy and Therapeutics Committee. For coverage details, review the MVP Formularies.

For additional pharmacy updates visit here.

A list of Plan Year 2026 formulary changes is available here: 2026 Commercial and Marketplace Formulary Changes. Changes take effect on the Member’s pharmacy plan year start date.

Drugs removed from prior authorization for Commercial, Marketplace and Self-Funded Formularies

• Blujepa®(gepotidacin)
• Vizz solution 1.44% OP™ (aceclidine)
• Zurnai™(nalmefene)

New Drugs excluded for Commercial, Marketplace and Self-Funded Formularies

• Brekiya®(dihydroergotamine)

New generics that recently came to market